Paul Y Song, MD, NKGen Biotech, Santa Ana, CA, expresses his optimism about the future of Alzheimer’s disease treatment. Dr Song and his team are developing an autologous, non-genetically modified natural killer (NK) cell-based therapy which has shown promising findings in a recent Phase I trial. He is optimistic that efficacious therapies would have a significant impact on families and caregivers, as well as the patients themselves. For example, one patient treated with NK cell therapy regained their ability to walk, giving them more independence and relieving burden on their caretakers. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2023 in Amsterdam, Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.